Back to Archived Journals » Biosimilars » Volume 3
Biosimilars ceased publishing in October 2016. All new submissions can be made to Biologics: Targets and Therapy. All articles that have been published in Biosimilars will continue to be available on the Dove Press site, and will be securely archived with CLOCKSS.
Biosimilars
ISSN: 2230-245X
- View all (31)
- Volume 6, 2016 (6)
- Volume 5, 2015 (9)
- Volume 4, 2014 (4)
- Volume 3, 2013 (6)
- Volume 2, 2012 (4)
- Volume 1, 2011 (2)
Archive: Volume 3, 2013
Clinical efficacy and safety of Tevagrastim® (XM02), a biosimilar recombinant human granulocyte colony-stimulating factor
Bagalagel A, Mohammed A, MacDonald K, Abraham I
Biosimilars 2013, 3:55-62
Published Date: 27 August 2013
Clinical efficacy and safety of XM01, a biosimilar recombinant human erythropoietin, in the management of anemia
Mohammed A, Bagalagel A, MacDonald K, Abraham I
Biosimilars 2013, 3:45-53
Published Date: 27 August 2013
Clinical efficacy and safety of SB309, a biosimilar recombinant human erythropoietin, in the management of anemia
Bagalagel A, Mohammed A, MacDonald K, Abraham I
Biosimilars 2013, 3:35-43
Published Date: 21 August 2013
Current and future biosimilars: potential practical applications in rheumatology
Noaiseh G, Moreland L
Biosimilars 2013, 3:27-33
Published Date: 1 August 2013
Rituximab and biosimilars – equivalence and reciprocity
Qureshi ZP, Magwood JS, Singh S, Bennett CL
Biosimilars 2013, 3:19-25
Published Date: 14 June 2013
Similar biotherapeutic products in Latin America. Regulation and opportunities for patients with autoimmune diseases
Desanvicente-Celis Z, Caro-Moreno J, Enciso-Zuluaga M, Anaya JM
Biosimilars 2013, 3:1-17
Published Date: 4 January 2013